Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy

Overview

Journal Diseases

Date 2022 Jul 27

PMID 35892735

Authors

Puri Ferreros

Isabel Trapero

Affiliations

Soon will be listed here.

Abstract

Introduction: Chimeric antigen receptor T-cell (CAR-T) therapy is an innovative therapeutic option for addressing certain recurrent or refractory hematological malignancies. However, CAR-T cells also cause the release of pro-inflammatory cytokines that lead to life-threatening cytokine release syndrome and neurotoxicity.

Objective: To study the efficacy of interleukin inhibitors in addressing cytokine release syndrome (CRS) and neurotoxicity secondary to CAR-T therapy.

Methodology: The authors conducted a bibliographic review in which 10 articles were analyzed. These included cut-off studies, case reports, and clinical trials involving 11 cancer centers and up to 475 patients over 18 years of age.

Results: Tocilizumab is the only interleukin inhibitor approved to address CRS secondary to CAR-T therapy due to its efficacy and safety. Other inhibitors, such as siltuximab and anakinra, could be useful in combination with tocilizumab for preventing severe cytokine release and neurotoxicity. In addition, the new specific inhibitors could be effective in mitigating CRS without affecting the cytotoxic efficacy of CAR-T therapy.

Conclusion: More lines of research should be opened to elucidate the true implications of these drugs in treating the side effects of CAR-T therapy.

Citing Articles

Gastric Cancer Signaling Pathways and Therapeutic Applications.

Wu M, Yuan S, Liu K, Wang C, Wen F Technol Cancer Res Treat. 2024; 23:15330338241271935.

PMID: 39376170 PMC: 11468335. DOI: 10.1177/15330338241271935.

DeltaRex-G, tumor targeted retrovector encoding a CCNG1 inhibitor, for CAR-T cell therapy induced cytokine release syndrome.

Haroun G, Gordon E Front Mol Med. 2024; 4:1461151.

PMID: 39359418 PMC: 11445129. DOI: 10.3389/fmmed.2024.1461151.

IL-1 Family Blockade in Cytokine Storm Syndromes.

Cron R Adv Exp Med Biol. 2024; 1448:553-563.

PMID: 39117838 DOI: 10.1007/978-3-031-59815-9_36.

Unveiling novel insights into human IL-6 - IL-6R interaction sites through 3D computer-guided docking and systematic site mutagenesis.

Li K, Cai J, Jiang Z, Meng Q, Meng Z, Xiao H Sci Rep. 2024; 14(1):18293.

PMID: 39112658 PMC: 11306327. DOI: 10.1038/s41598-024-69429-w.

The Kinetics of Inflammation-Related Proteins and Cytokines in Children Undergoing CAR-T Cell Therapy-Are They Biomarkers of Therapy-Related Toxicities?.

Marschollek P, Liszka K, Mielcarek-Siedziuk M, Dachowska-Kalwak I, Haze N, Panasiuk A Biomedicines. 2024; 12(7).

PMID: 39062195 PMC: 11275041. DOI: 10.3390/biomedicines12071622.

References

Lee D, Gardner R, Porter D, Louis C, Ahmed N, Jensen M . Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-95. PMC: 4093680. DOI: 10.1182/blood-2014-05-552729. View

Abramson J, Palomba M, Gordon L, Lunning M, Wang M, Arnason J . Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254):839-852. DOI: 10.1016/S0140-6736(20)31366-0. View

Brentjens R, Davila M, Riviere I, Park J, Wang X, Cowell L . CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013; 5(177):177ra38. PMC: 3742551. DOI: 10.1126/scitranslmed.3005930. View

Chen H, Wang F, Zhang P, Zhang Y, Chen Y, Fan X . Management of cytokine release syndrome related to CAR-T cell therapy. Front Med. 2019; 13(5):610-617. DOI: 10.1007/s11684-019-0714-8. View

Figuero-Perez L, Olivares-Hernandez A, Escala-Cornejo R, Teran-Brage E, Lopez-Gutierrez A, Cruz-Hernandez J . Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab. Reumatol Clin (Engl Ed). 2021; 17(10):559-561. PMC: 7561306. DOI: 10.1016/j.reumae.2020.06.008. View

Nellan A, Lester McCully C, Cruz Garcia R, Jayaprakash N, Widemann B, Lee D . Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques. Blood. 2018; 132(6):662-666. PMC: 6086204. DOI: 10.1182/blood-2018-05-846428. View

Harris D, Kranz D . Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors. Trends Pharmacol Sci. 2015; 37(3):220-230. PMC: 4764454. DOI: 10.1016/j.tips.2015.11.004. View

Rice J, Nagle S, Randall J, Hinson H . Chimeric Antigen Receptor T Cell-Related Neurotoxicity: Mechanisms, Clinical Presentation, and Approach to Treatment. Curr Treat Options Neurol. 2019; 21(8):40. DOI: 10.1007/s11940-019-0580-3. View

Catino A . Cytokines Are at the Heart of It: Cytokine Release Syndrome Underlies Cardiovascular Effects of CAR T Cell. JACC CardioOncol. 2021; 2(2):204-206. PMC: 8352284. DOI: 10.1016/j.jaccao.2020.05.006. View

10.

Kohl U, Abken H . [CAR T cells as drugs for novel therapies (advanced therapy medicinal products)]. Internist (Berl). 2021; 62(4):449-457. DOI: 10.1007/s00108-021-00953-x. View

11.

Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M . Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018; 24(6):739-748. DOI: 10.1038/s41591-018-0036-4. View

12.

Marzal-Alfaro M, Escudero-Vilaplana V, Revuelta-Herrero J, Collado-Borrell R, Herranz-Alonso A, Sanjurjo-Saez M . Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective. Front Oncol. 2021; 11:636068. PMC: 7992774. DOI: 10.3389/fonc.2021.636068. View

13.

Neelapu S, Tummala S, Kebriaei P, Wierda W, Locke F, Lin Y . Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol. 2018; 15(4):218. PMC: 6716606. DOI: 10.1038/nrclinonc.2018.20. View

14.

Sheth V, Gauthier J . Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. Bone Marrow Transplant. 2020; 56(3):552-566. PMC: 8592274. DOI: 10.1038/s41409-020-01134-4. View

15.

Scholler J, Brady T, Binder-Scholl G, Hwang W, Plesa G, Hege K . Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med. 2012; 4(132):132ra53. PMC: 4368443. DOI: 10.1126/scitranslmed.3003761. View

16.

Hu L, Charwudzi A, Li Q, Zhu W, Tao Q, Xiong S . Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R/R B-ALL patients: a systematic review and meta-analysis. Ann Hematol. 2021; 100(4):1003-1012. DOI: 10.1007/s00277-021-04451-w. View

17.

Zhang X, Lu X, Yang J, Zhang G, Li J, Song L . Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood Adv. 2020; 4(10):2325-2338. PMC: 7252549. DOI: 10.1182/bloodadvances.2020001466. View

18.

Burns E, Gentille C, Trachtenberg B, Pingali S, Anand K . Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management. Diseases. 2021; 9(1). PMC: 8006027. DOI: 10.3390/diseases9010020. View

19.

Fraietta J, Beckwith K, Patel P, Ruella M, Zheng Z, Barrett D . Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016; 127(9):1117-27. PMC: 4778162. DOI: 10.1182/blood-2015-11-679134. View

20.

Pan J, Yang J, Deng B, Zhao X, Zhang X, Lin Y . High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients. Leukemia. 2017; 31(12):2587-2593. DOI: 10.1038/leu.2017.145. View